AzTrials
AzTrials

Furcation DefectsFURC-III-OSTNCT04017429

Osteoplasty in Conjunction With Surgical Treatment of Mandibular Grade III Furcation Defects (FURC-III-OST)

A study testing Open flap debridement with osteoplasty and Open flap debridement without osteoplasty in people with Furcation Defects and Periodontal Diseases, run by University of Oslo at 1 site in Norway.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Teeth with furcation grade III defects will be treated with open flap debridement, with or without osteoplasty. The study is designed to examine the effect of osteoplasty in the treatment of teeth with furcation grade III defects with open flap debridement. Read more about this study

Who is it for?
Ages 20 years and olderHealthy volunteers can take part
Conditions the study is for
Furcation Defects, Periodontal Diseases
What is being tested?
Open flap debridement with osteoplasty and Open flap debridement without osteoplasty
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteNorway
Study dates
15 Oct 2019to 15 Jun 2027
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Periodontal disease stage III or IV according to 2018 criteria
  • Undergoing periodontal therapy (active or supportive) and present 1 or more pair of bilateral mandibular molars affected by furcation involvement grade III with PPD>4mm, and the furcation fornix must be above a tangential line from the distal to mesial interproximal crestal bone level on bitewing radiographs
  • Competent to give consent

Who cannot join

  • Previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment
  • Present or past use of bisphosphonate treatment
  • Pregnant or nursing subjects
  • Patients classified as > class II according to ASA classification
  • Previous surgical therapy of included furcation defects
  • Inhability to comprehend and respond to the quality of life questionnaire
Show all 10Show fewer
  • Dental restorations or prosthesis involving the furcation area
  • Root fractures or suspected fractures/infractions
  • Caries lesoins in the furcation area
  • No systemic antibiotic treatment within 3 months prior to intervention

Trial locations and contacts

1 site in 1 country.

Norway1 site
  • Institute of Clinical Dentistry, University of Oslo, Norway

    Oslo

Other trials in Norway

About this study

Official title: Treatment of Grade III Furcation Defects in Teeth With Low Interproximal Crestal Bone Height, With and Without Osteoplasty, in Conjunction With Open Flap Debridement

Teeth with furcation grade III defects will be treated with open flap debridement, with or without osteoplasty. The study is designed to examine the effect of osteoplasty in the treatment of teeth with furcation grade III defects with open flap debridement.

Being tested
Open flap debridement with osteoplasty, Open flap debridement without osteoplasty
Medical subject headings
Furcation Defects, Periodontal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Open flap debridement with osteoplastyProcedure or surgery

    Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to >90 degrees relative to the apico-coronal axis of the tooth.

  • Open flap debridement without osteoplastyProcedure or surgery

    Treatment of furcation grade III defect with open flap debridement only.

Study groups in NCT04017429
Study groupRoleWhat they receive
Open flap debridement with osteoplastyExperimentalIn this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
Receives: Procedure: Open flap debridement with osteoplasty; Procedure: Open flap debridement without osteoplasty
Open flap debridement without osteoplastyActive comparatorIn this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
Receives: Procedure: Open flap debridement with osteoplasty; Procedure: Open flap debridement without osteoplasty

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sites with no signs of inflammation

    Proportion of sites without inflammation, defined as no BoP or PPD>4mm following treatment

    Measured: 12 months after treatment

  2. Sites with no signs of inflammation

    Proportion of sites without inflammation, defined as no BoP or PPD>4mm following treatment

    Measured: 24 months after treatment

Secondary outcomes (7)
  1. Changes in patient-reported quality of life (QoL)

    To assess QoL changes related to mouth and teeth prior to therapy to after therapy by the use of "The Oral Impacts on Daily Performance (OIDP)" instrument. Each question is assessed by a 5-point scale; (1) never affected; (2) less than once a month; (3) once or twice a month; (4) once or twice a week; and (5) every or nearly every day. The higher number represents more severe impact on quality of life; e.g. worse outcome.

    Each item will be dichotomised yielding the categories (A) affected; including scale categories (2)-(5), and (B) unaffected; including category (1)

    Measured: Preoperatively compared to 24 months after treatment

  2. Changes in patient-reported quality of life (QoL)

    To assess QoL changes related to mouth and teeth prior to therapy to after therapy by the use of "The Oral Impacts on Daily Performance (OIDP)" instrument. Each question is assessed by a 5-point scale; (1) never affected; (2) less than once a month; (3) once or twice a month; (4) once or twice a week; and (5) every or nearly every day. The higher number represents more severe impact on quality of life; e.g. worse outcome.

    Each item will be dichotomised yielding the categories (A) affected; including scale categories (2)-(5), and (B) unaffected; including category (1)

    Measured: Preoperatively compared to 12 months after treatment

  3. Loss of clinical attachment level

    To assess further loss of clinical attachment level by the use of a periodontal probe

    Measured: 12 months after treatment

  4. Loss of clinical attachment level

    To assess further loss of clinical attachment level by the use of a periodontal probe

    Measured: 24 months after treatment

  5. Number of participants with caries lesions

    To assess caries lesions in furcation defects following therapy. Caries lesions are assessed clinically with an explorer as caries (Y/N)

    Measured: 24 months after treatment

  6. Radiographic changes

    To assess bone loss as measured on standardized radiographs (in mm)

    Measured: 12 months after treatment

  7. Radiographic changes

    To assess bone loss as measured on standardized radiographs (in mm)

    Measured: 24 months after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jul 2019
  2. Study start15 Oct 2019
  3. Primary completion15 Jun 2027 (estimated)
  4. Study completion15 Jun 2027 (estimated)

Why it stopped: Not feasible to recruit and follow-up subjects due to the pandemic

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04017429
Sponsor's protocol ID
FURC-III-OST
Acronym
FURC-III-OST
Status last verified
Apr 2021
First submitted
8 Jul 2019
Last updated
30 Apr 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Open flap debridement with osteoplasty and Open flap debridement without osteoplasty in people with Furcation Defects and Periodontal Diseases, run by University of Oslo at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 30 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sites with no signs of inflammation (time frame: 12 months after treatment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in